Meloxicam 7.5mg treatment of osteoarthritis, spinal inflammation (2 blisters x 10 tablets)

Dosage form Box of 2 blisters x 10 tablets
Specifications Meloxicam

Ingredient

Composition information	Content
Meloxicam	7.5mg

Uses

Indications

Meloxicam 7.5mg Domesco is indicated in the following cases:

osteoarthritis and rheumatoid arthritis: Meloxicam is indicated to reduce the signs and symptoms of osteoarthritis and rheumatoid arthritis.

Adolescents (JRA) formation of arthritis and polyarthritis: Meloxicam is indicated that reduces the signs and symptoms of teenage rheumatoid arthritis (JRA) with low arthritis and polyarthritis in patients 2 years old or older.

Pharmacokology

Pharmacological group: Non-Stoid anti-inflammatory drugs. Meloxicam has analgesic, anti -inflammatory, anti -fever.

Meloxicam's acting mechanism is like other NSAID drugs, not fully understood but related to cyclooxygenase inhibition (COX-1 and COX-2).

Meloxicam has the ability to inhibit the synthesis of prostaglandin in vitro. Meloxicam concentration is achieved in the therapy for Vivo printing effect. Prostaglandin senses the nerves of the mind and activates the pain effect of Bradykinin in animal models. Prostaglandin are intermediate inflammatory substances. Because Meloxicam is a prostaglandin synthesis inhibitor, the effect of meloxicam may be due to reducing prostaglandin in peripherals.

pharmacokinetics

absorption:

Meloxicam's absolute bioavailability is 89 % after taking a single dose of 30 mg. After multi -dose taken, pharmacokinetics of linear meloxicam between 7.5 mg to 15 mg.

Oral Meloxicam after a high -fat breakfast (75 g of fat) will increase the medium peak concentration of the drug (CMJ is about 22 % while the level of absorption (AUC) is constant. The time reaches a maximum concentration of about 5 to 6 hours. No pharmacokinetic interaction when used simultaneously with antacids.

Distribution:

The average distribution of Meloxicam is about 10 liters. In humans, Meloxicam is connected to plasma protein 99.4% (mainly albumin) in the treatment dose. After drinking, Meloxicam penetrates the red blood cell cells of the person less than 10%.

After a dose, Meloxicam concentration in the epidemic is equivalent to 40 % to 50 % compared to plasma. The freedom in the epidemic is 2.5 times higher in plasma due to the lower albumin in the epidemic than the plasma.

Metabolism:

Meloxicam is metabolized mainly in the liver. The metabolites of Meloxicam ceramic 5'-carboxy meloxicam (about 60 % used), formed through P450 by the oxidation of intermediate chemical chemical chemicals 5'-hydroxymethyl meloxicam, this substance is also excreted in less amount (about 9 % dose).

Peroxidase activity of patients produces two other passing substances, accounting for 16 % and 4 % of the dose.

Era:

Meloxicam is excreted mainly in the form of metabolites in the same level in urine and feces. Only a very small amount of untreated substance is eliminated in urine (0.2 %) and in feces (1.6 %).

The level of deduction through water is recorded for multiple doses of 7.5 mg: encroachment is 0.5 %, 6 % and 13 % of the dose found in urine in the form of meloxicam, metabolic 5'-hydroxymethyl and 5'-carboxy. There is a significant elimination of the drug through bile and/or intestinal. This proves that when taking cholestyramin after a single -dose of intravenous melo, it will reduce the AUC of Meloxicam by about 50 %.

The average selling time is about 15 to 20 hours. Plasma clearance from 7 to 9 ml/min.

Before taking Meloxicam 7.5mg treatment of osteoarthritis, spinal inflammation (2 blisters x 10 tablets)

How to use

Consider carefully between Meloxicam's benefits and potential risks and select other treatments before deciding to use Meloxicam. Using the lowest dose is effective in the shortest time suitable for the treatment goals for each patient.

Dosage

After observing the patient responds to the initial treatment with Meloxicam, the dose adjustment should be adjusted to suit the response of each patient.

In adults, Meloxicam's maximum daily recommendation is 15 mg. In patients with hemolysis, the maximum daily recommended dose is 7.5 mg.

osteoarthritis and rheumatoid arthritis:

The recommended starting and maintenance dose of Meloxicam is 7.5 mg, 1 time/day. Some patients may increase the dose to 15 mg, 1 time/day.

Early rheumatoid arthritis is less arthritis and polyarthritis:

To improve the accuracy of children's dosage, it is advisable to use other cell formidated melasoms that are suitable for children.

To treat teenage rheumatoid arthritis, Meloxicam's recommended dose is 0.125 mg/kg, 1 time/day, up to 7.5 mg/day. There is no additional evidence to increase the dose above 0.125 mg/kg/day in clinical trials.

The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? There is no specific antidote. Consider causing vomiting and/or using activated carbon (60 g to 100 g for adults, 1 g to 2g/kg of weight for children) and/or osmotic bleach for patients with symptoms within 4 hours after overdose or for patients with severe overdose. Forced diuretic, alkaline urine, hemolysis or dialysis may not work due to high ability to cohesion with protein.

Only limited experience in Meloxicam overdose. Cholestyramin is known to increase Meloxicam excretion. Drinking 4 g cholestyramin, 3 times a day increases the elimination of Meloxicam has been proven in clinical trials. Using cholestyramin may work when overdose.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Meloxicam 7.5mg Domesco, you may experience unwanted effects (ADR).

Unknown frequency:

Systemic: allergic reactions, facial edema, fatigue, fever, hot burning, discomfort, fainting, weight loss, weight gain.

Cardiovascular system: angina, heart failure, hypotension, hypertension, myocardial infarction, vasculitis.

Risk of cardiovascular thrombosis.

Instructions on how to handle ADR:

To minimize the undesirable effect on Meloxicam's gastrointestinal tract, take medicine immediately after eating or used in combination with antacids and protecting the stomach lining.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Meloxicam drug 7.5mg domesco contraindicated in the following cases:

Hypersensitivity to Meloxicam or any ingredients of the drug.

Patients with a history of asthma, urticaria or other allergic reactions after using aspirin or other NSAID drugs. Serious hypersensitivity reactions with NSAID drugs, sometimes fatal, have been reported in these patients.

Coronary cavity (CABG) surgery.

Caution when using

cardiovascular thrombosis:

Doctors need to periodically evaluate the appearance of cardiovascular events, even if the patient has no previous cardiovascular symptoms. Patients should be warned of symptoms of serious cardiovascular events and need to visit the doctor as soon as they appear.

Patients after myocardial infarction:

Avoid using Meloxicam in patients with recent myocardial infarction unless the benefits are higher than the risk of recurrent cardiovascular thrombosis. If Meloxicam is used for patients with recent myocardial infarction, it is necessary to monitor the signs of local myocardial ischemia.

ulcer, hemorrhage and gastrointestinal perforation:

Use the lowest doses effectively in the shortest possible time.

Avoid using more than 1 NSAID medicine at the same time.

Avoid use in patients at high risk unless the benefits are higher than the risk of bleeding. For these patients, as well as for patients with gastrointestinal bleeding, they should consider replacing NSAID with other drugs.

Maintain a warning of signs and symptoms of ulcer and gastrointestinal bleeding during NSAID treatment.

If there is suspicion of serious events of the gastrointestinal tract, evaluating and treating immediately, stop using Meloxicam until this event is no longer available.

When using aspirin at low doses to prevent cardiovascular disease, patients should be monitored on signs of gastrointestinal bleeding.

Liver poisoning:

Notify the patient about the signs and symptoms of liver damage. If there are signs and clinical symptoms of progressive liver disease, or if there is a systemic symptom, stop using Meloxicam and perform clinical assessments for patients.

Hypertension:

Should monitor blood pressure during the treatment period with NSAID.

heart failure and edema:

Avoid using Meloxicam for patients with severe heart failure unless the benefits are higher than the risk of heart failure. If using Meloxicam for patients with severe heart failure, should monitor the severe signs of heart failure.

Kidney toxicity:

Adjust the volume of circulatory volume in patients to reduce the volume or dehydration before using Meloxicam. Monitoring the kidney function in patients with liver or renal failure, heart failure, dehydration or decrease in the body during the use of Meloxicam.

Avoid using Meloxicam in patients with renal disease progresses unless the benefits are higher than the puppet muscle, which reduces the kidney function. If using Meloxicam in patients with progressive renal disease, monitor signs of impaired renal function in patients.

Hyperbonemia:

Increased blood potassium concentration has been reported when using NSAID, even in some patients without kidney failure.

Acute asthma due to aspirin sensitivity: When using Meloxicam for patients with a history of asthma (not sensitive to aspirin), it is necessary to monitor the signs and symptoms of asthma.

Serious skin reactions:

Information for patients about signs and symptoms of serious skin reactions, stop using meloxicam when there is a skin rash or any hypersensitive signs. Contraindicated to use Meloxicam for patients with serious skin reactions to NSAID earlier.

Blood toxicity:

If the patient is treated with Meloxicam with anemia symptoms, hemoglobin or hematocrit.

Hide signs of inflammation and fever:

Meloxicam's anti -inflammatory and antipyretic effects can hide signs of bacterial diagnosis.

The ability to drive and operate machinery

The drug can cause dizziness and drowsiness. Therefore, it is necessary to be cautious when used for trainers, operating machinery.

Pregnancy

There is no complete and well -controlled study in pregnant women. Meloxicam passed through the placenta fence. Pregnant women 30 weeks before, only using Meloxicam during this pregnancy when the benefits are higher than the potential risk for the fetus.

Starting from 30 weeks of gestational age, avoiding Meloxicam and other NSAIDs for pregnant women because they can cause early clitchs of the ductus artery in the fetus. If Meloxicam is used during this period of pregnancy, warns patients with potential risks to the fetus.

The period of breastfeeding

It is unclear whether Meloxicam is excreted in breast milk or not. Because there are many drugs excreted in breast milk and due to the possibility of serious harmful reactions in breastfed babies using meloxicam, they should stop breastfeeding or stopping the drug, considering the importance of the drug for the mother.

Medicinal interaction

simultaneous use of meloxicam and cyclosporin increases the kidney toxicity of cyclosporin.

Use Meloxicam and other NSAID drugs or Salicylate (e.g. Diflunisal, Salsalate) increases the toxicity of the gastrointestinal tract that increases less or does not increase the effectiveness of treatment.

Storage

Store in a dry place, temperatures below 30 ° C, avoiding light.

Storage in the original packaging of the drug.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.